Abstract 946: A novel monoclonal antibody targeting cell-surface plectin has potent antitumor activity in ovarian cancer models
Authors: Samantha Melinda Perez, Julien Dimastromatteo, Kimberly A. Kelly
Journal: Cancer Research (2021)

Abstract Background: Cell surface plectin (CSP) is an abundant bioavailable target exclusively found on the surface of ovarian epithelial cancers while remaining entirely intracellular in pre-malignant tissue. Under current treatment options, 80% of women, even if remission is achieved, will experience recurrence of disease demonstrating an urgent need for more effective therapeutics. Herein, we investigate the anticancer effects of a CSP-targeting monoclonal antibody (ZB131) in in-vitro and in-vivo models of ovarian cancer (OC) as well as elucidate key signaling pathways it modulates. We demonstrate that treatment with ZB131 is efficacious both as a monotherapy and in combination with chemotherapy. Methods: A first-in-class CSP-targeting monoclonal antibody, ZB131, was developed and characterized for specificity and affinity via ELISA and kinetic binding assays. In-vitro efficacy of ZB131 was determined by Cell Titer-Glo assay and flow cytometry, impact on cell-cycle by flow cytometry, and on migration by scratch assay using multiple OC cell lines. ROS accumulation was evaluated by DCFDA assay. Phosphorylation changes of signaling kinases were measured by LiCor. In-vivo validation was performed in an OC xenograft model. The expression of proliferative markers was evaluated by IHC staining of tumor sections. Treatment toxicity was assessed from serum chemistry tests and histological evaluation of major organs. Similar in-vivo and in-vitro techniques were used to characterize ZB131's effect in combination with cisplatin. Results: ZB131 demonstrates high affinity (0.4±0.1nM) and specificity for both murine and human CSP. Treatment with ZB131 decreased cell proliferation, migration, induced G0/G1 growth arrest, and increased ROS accumulation followed by cell death in OC cell lines. ZB131 induced two coordinated events, decreased phosphorylation of cell proliferation cascades (AKT, PRAS40, ERK1/2, and GSK3alpha/beta) and increased phosphorylation of stress signaling pathways (JNK, c-Jun, p38, MSK1/2, and AMPK). In vivo, ZB131 therapy caused a 50% tumor growth reduction as well as decreased expression of cyclin D and Ki67 with no toxic side effects. Impressively, ZB131 synergizes with cisplatin resulting in a greater than 50-fold decrease in IC50 in-vitro and showed sustained tumor growth reduction with greater than 85% tumor necrosis over the course of treatment in-vivo. Conclusion: CSP is a novel highly abundant therapeutic target exclusively localized to the cell surface of ovarian, colorectal, lung, and pancreatic cancers which collectively account for more than half of all estimated cancer deaths. Our findings illustrate that CSP-targeting with ZB131 induces cytotoxicity by activating stress pathways and dampening proliferation and survival pathways. This study serves as the basis for informing a novel treatment strategy for CSP-positive tumors. Citation Format: Samantha Melinda Perez, Julien Dimastromatteo, Kimberly A. Kelly. A novel monoclonal antibody targeting cell-surface plectin has potent antitumor activity in ovarian cancer models [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 946.